Twitter Beğeni Hilesi

Our #TranslationalMedicine link of the week, chosen by SWOG Cancer Research Network's Lee Ellis & Jimmy Rae, PhD: Targeting Chromosomal Instability in Patients with Cancer doi.org/10.1038/s41571…

Phenomenal talk from the master himself Sumanta K. Pal, MD, FASCO on the role of gut microbiome to optimize immunotherapy in cancer. Showcasing the work his group has done with Nazli Dizman Hedyeh Ebrahimi with back to back nature papers Promising avenue that will lay the foundation for a SWOG Cancer Research Network

For patients without a matching substudy, #myeloMATCH follows them on their standard-of-care treatment via the Tier Advancement Pathway (TAP), rescreening them later for a possible future substudy. National Cancer Institute @Alliance_org CCTG ECOG-ACRIN Cancer Research Group SWOG Cancer Research Network swog.org/myeloMATCH

Application open now #SWOGonc thehopefoundation.org/funding-opport…

S1900K is a new Lung-MAP sub-study that tests combining ramucirumab and tepotinib for non-small cell #lungcancer that has a SWOG.org/S1900K. Or call 1-800-4-CANCER. #lcsm #nsclc @GO2Foundation

Lung-MAP is a #clinicaltrial that tests patients’ cancer cells for gene changes. If you have non- small cell #lungcancer with a MET exon 14 skipping gene change, you may be eligible for Lung-MAP’s S1900K study. Visit SWOG.org/S1900K. Or call 1-800-4-CANCER. #lcsm #nsclc

Do you have non-small cell #lungcancer that has a MET exon 14 skipping gene change? If you had previous treatment and the cancer has gotten worse, you may be eligible for Lung-MAP's S1900K study. Learn more at SWOG.org/S1900K. Or call 1-800-4-CANCER. #lcsm #nsclc

.SWOG Cancer Research Network S1937 in metastatic #urothelialcarcinoma has reopened to enrollment. Revised study compares eribulin + gemcitabine combo to SOC (eribulin-only arm has closed). #bladdercancer #mUC PI: Sarmad Sadeghi, MD, PhD USC Norris Comprehensive Cancer Center SWOG.org/clinical-trial…

Our #TranslationalMedicine links of the week (2 this week!), chosen by SWOG Cancer Research Network's Lee Ellis & Jimmy Rae, PhD: 1) Natural Killer Cells and Engagers: Powerful Weapons Against Cancer doi.org/10.1111/imr.13…

Our #TranslationalMedicine links of the week (2 this week!), chosen by SWOG Cancer Research Network's Lee Ellis & Jimmy Rae, PhD: 2) Tumor Is Not the Only Target: Ensuring Equitable Person-Centered Supportive Care in the Era of Precision Medicine doi.org/10.1200/EDBK_4…

#Lungcancer study S1900K asks if adding ramucirumab to tepotinib treatment can lessen the side effect of swelling in the arms and legs. It’s for people with cancer that has a METex14-skipping gene change. Learn more at SWOG.org/S1900K. Or call 1-800-4-CANCER. #lcsm #nsclc

Our C Blanke, SWOG Chair blog: Patient-Reported Outcomes (PROs): Engaging Your Core! SWOG Cancer Research Network's PRO Core works with investigators to incorporate PROs and quality-of-life measures into #NCORP and #NCTN trials. Five years on, many accomplishments to report! swog.org/news-events/ne…

. SWOG Cancer Research Network S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - Dr. Amrita Krishnan Hoering, Phari Sexton, Robert Z. Orlowski #ASH20 Abst 1515 ow.ly/U9xg50FYWgt #NCT04071457 #mmsm

New Friends perspective in ESMO - Eur. Oncology RWD & Digital Health discusses the potential of incorporating pragmatic elements in oncology clinical trials. #PragmaticTrials are a promising way to achieve more efficient, relevant, & patient-centered drug development. bit.ly/4cAkUOz

The Lung-MAP precision medicine trial’s S1900K sub-study randomizes patients w MET exon 14 skipping-positive advanced non-small cell #lungcancer to tepotinib w/wo ramucirumab. PI: Paul K. Paik, MD BenWellington. An ECOG-ACRIN Cancer Research Group sub-study. SWOG.org/clinical-trial… #NSCLC #lcsm

Gene mutations associated with response to cisplatin-based chemotherapy in MIBC urologytimes.com/view/gene-muta… via @urologytimes Analysis from the SWOG Cancer Research Network S1314 trial. Elizabeth Plimack MD Fox Chase Cancer Center David McConkey Thomas Flaig splernerMD

.Lung-MAP S1900K is now enrolling patients with METex14-skipping #NSCLC. Hypothesis: resistance to MET inhibition in these patients is due to VEGFR2 signaling. Tests adding ramucirumab to MET inhibitor tepotinib. Co-PI: Xiuning Le MD PhD MD Anderson Cancer Center SWOG.org/clinical-trial…

S1900K Lung-MAP sub-study randomizes patients w MET exon 14 skipping+ #NSCLC to tepotinib w/wo ramucirumab. Local CLIA-lab documentation of METex14-skipping biomarker may be used. Lead statistician: Mary Redman, PhD SWOG Cancer Research Network @FredHutch UW Biostatistics SWOG.org/clinical-trial…

Our #TranslationalMedicine link of the week, chosen by SWOG Cancer Research Network's Lee Ellis & Jimmy Rae, PhD: Bispecific Antibodies: Advancing Precision Oncology doi.org/10.1016/j.trec…

Our C Blanke, SWOG Chair blog: More DART Results, and the Birth of DART II Adrenocortical carcinoma is the latest rare cancer to show a benefit from the SWOG Cancer Research Network DART trial's regimen, and I’m pleased to report that development of DART II is well underway. swog.org/news-events/ne…